FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer
Fudan University
Fudan University
Ottawa Hospital Research Institute
University of Chicago
Centre Francois Baclesse
Sanofi
Fudan University
GT Medical Technologies, Inc.
Bayer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
M.D. Anderson Cancer Center
Kyowa Kirin Co., Ltd.
Clinigen, Inc.
Myriad Genetic Laboratories, Inc.
Spanish Breast Cancer Research Group
Spanish Breast Cancer Research Group
Ataturk University
Centre hospitalier de l'Université de Montréal (CHUM)
Hoffmann-La Roche
Universitätsklinikum Hamburg-Eppendorf
Jiangsu HengRui Medicine Co., Ltd.
Qianfoshan Hospital
Palleos Healthcare GmbH
Hospital Universitari de Bellvitge
American University of Beirut Medical Center
The University of Texas Medical Branch, Galveston
Korea University
Astellas Pharma Inc
iOMEDICO AG
Qidong Gaitianli Medicines Co., Ltd
Novartis
Ain Shams Maternity Hospital
Novartis
Novartis
Hoffmann-La Roche
Eisai Inc.
Hoffmann-La Roche
Centre Francois Baclesse
Bispebjerg Hospital
Bayer
Fudan University
Centro Superior de Investigación en Salud Publica
Fudan University
University of Florida
Novartis
Hospices Civils de Lyon
National Institutes of Health Clinical Center (CC)
Dermatologic Cooperative Oncology Group